Our R&D Pipeline

Phase II Ready Small Molecule: MCHR1 Antagonist CSTI-100 for Nonalcoholic Steatohepatitis (NASH)

  • NASH affects about 16 million Americans and is set to become one of the next epidemic-level chronic diseases. It's set to surpass hepatitis as the biggest reason for liver transplants by 2020. There is no approved treatment for NASH yet.
  • Multi-factorial treatment for all hallmark symptoms in rodent models - reductions in key liver inflammatory, fibrosis and injury biomarkers; reductions in liver fat (triglycerides and non-esterified fatty acids) and cholesterol; improvements in liver histology; fat-selective weight loss due to reduction in food intake; improvements in glucose tolerance and insulin sensitivity; better efficacy vs two other agents that have shown efficacy in clinical trials of NASH.
  • Treatment for early to late stage NASH – current anti-fibrotic/inflammatory approaches expected to only be useful for late-stage NASH.
  • Safe and well tolerated in Phase I clinical studies, oral t1/2 of 26 h.
  • *We also welcome academic researchers to contact us for the possibility of a collaboration to study CSTI-100. Click here for more information on CSTI-100.

    Phase II ready asset: Triple Reuptake Inhibitor CSTI-500 for Proder-Willi Syndrome (PWS)

  • Prader-Willi syndrome is a rare genetic disorder affecting approximately 1 in 15,000 people and there is no adequate treatment.The hallmark symptom of PWS is hyperphagia or insatiable appetite which causes obesity. Most PWS patients also suffer from psychiatric and behavioral disorders such as temper tantrums, social isolation, anxiety, OCD, learning and cognitive disabilities. They often also suffer from excessive daytime sleepiness and sleep apnea.
  • Appropriately balanced “triple pharmacology” is expected to address the hallmark symptoms of Prader-Willi syndrome, particularly the hyperphagia, behavioral issues, and sleep disorder
  • Weight loss and reduction of appetite observed in Phase I
  • High serotonin transporter (SERT), low-mid norepinephrine (NET), and dose-dependent dopamine transporter (DAT) occupancy
  • Human CNS receptor occupancy studies completed to confirm target engagement and guide Phase II dosing
  • Potential for highly differentiated treatment for multiple other CNS indications: depression, binge-eating disorder, ADHD, excessive day time sleepiness
  • CSTI-300: Novel targeting of the 5-HT3 Receptor to Treat Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) and IBS with alternating constipation and diarrhea (IBS-M).

  • Irritable Bowel Syndrome (IBS) is a major functional disorder affecting 12% of adults with considerable economic burden (>$25 billion)
  • There is currently no effective treatment widely available
  • CSTI-300 is a 5-HT3 receptor partial agonist, expected to deliver such best-in-class treatment
  • Represents a new clinical approach; designed to avoid the side effects associated with maximal 5-HT3 receptor inhibition (i.e. severe constipation, ischemic colitis)
  • Excellent efficacy in translational preclinical models
  • Excellent drug properties and safety profile
  • Please contact info@consynance.com for a non-confidential deck